Engineered Heart Muscle Allografts for Heart Repair in Primates and Humans

Cardiomyocytes can be implanted to remuscularize the failing heart. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques. After confirmation of in vitro and in vivo (nude rat model) equivalence of the newly developed rhesus macaque EHM model with a previously established Good Manufacturing Practice-compatible human EHM formulation, long-term retention (up to 6 months) and dose-dependent enhancement of the target heart wall by EHM grafts constructed from 40 to 200 million cardiomyocytes/stromal cells were demonstrated in macaques with and without myocardial infarction-induced heart failure. In the heart failure model, evidence for EHM allograft-enhanced target heart wall contractility and ejection fraction, which are measures for local and global heart support, was obtained. Histopathological and gadolinium-based perfusion magnetic resonance imaging analyses confirmed cell retention and functional vascularization. Arrhythmia and tumour growth were not observed. The obtained feasibility, safety and efficacy data provided the pivotal underpinnings for the approval of a first-in-human clinical trial on tissue-engineered heart repair. Our clinical data confirmed remuscularization by EHM implantation in a patient with advanced heart failure.

References

Muller-Ehmsen J, Peterson K, Kedes L, Whittaker P, Dow J, Long T . Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation. 2002; 105(14):1720-6. DOI: 10.1161/01.cir.0000013782.76324.92. View

Shiba Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y . Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 2016; 538(7625):388-391. DOI: 10.1038/nature19815. View

Bremmer F, Pongratanakul P, Skowron M, Che Y, Richter A, Kuffer S . Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets. Br J Cancer. 2023; 129(10):1580-1589. PMC: 10645790. DOI: 10.1038/s41416-023-02425-5. View

Weinberger F, Breckwoldt K, Pecha S, Kelly A, Geertz B, Starbatty J . Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci Transl Med. 2016; 8(363):363ra148. DOI: 10.1126/scitranslmed.aaf8781. View

Becht E, McInnes L, Healy J, Dutertre C, Kwok I, Ng L . Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol. 2018; . DOI: 10.1038/nbt.4314. View

Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C . Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019; 37(3):252-258. PMC: 6419516. DOI: 10.1038/s41587-019-0016-3. View

Kim J, Nam Y, Rim Y, Ju J . Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells. Stem Cell Rev Rep. 2021; 18(1):142-154. PMC: 8445612. DOI: 10.1007/s12015-021-10262-3. View

Kupfer M, Lin W, Ravikumar V, Qiu K, Wang L, Gao L . In Situ Expansion, Differentiation, and Electromechanical Coupling of Human Cardiac Muscle in a 3D Bioprinted, Chambered Organoid. Circ Res. 2020; 127(2):207-224. PMC: 8210857. DOI: 10.1161/CIRCRESAHA.119.316155. View

Didie M, Christalla P, Rubart M, Muppala V, Doker S, Unsold B . Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. 2013; 123(3):1285-98. PMC: 3582145. DOI: 10.1172/JCI66854. View

10.

Zhao X, Chen H, Xiao D, Yang H, Itzhaki I, Qin X . Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction. Stem Cell Reports. 2018; 10(2):422-435. PMC: 5830958. DOI: 10.1016/j.stemcr.2018.01.002. View

11.

Romagnuolo R, Masoudpour H, Porta-Sanchez A, Qiang B, Barry J, Laskary A . Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias. Stem Cell Reports. 2019; 12(5):967-981. PMC: 6524945. DOI: 10.1016/j.stemcr.2019.04.005. View

12.

Trede F, Kil N, Stranks J, Connell A, Fischer J, Ostner J . A refined panel of 42 microsatellite loci to universally genotype catarrhine primates. Ecol Evol. 2021; 11(1):498-505. PMC: 7790618. DOI: 10.1002/ece3.7069. View

13.

Gnecchi M, He H, Liang O, Melo L, Morello F, Mu H . Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11(4):367-8. DOI: 10.1038/nm0405-367. View

14.

Yang H, Shao N, Holmstrom A, Zhao X, Chour T, Chen H . Transcriptome analysis of non human primate-induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer culture vs. 3D engineered heart tissue. Cardiovasc Res. 2020; 117(9):2125-2136. PMC: 8318103. DOI: 10.1093/cvr/cvaa281. View

15.

Gao L, Gregorich Z, Zhu W, Mattapally S, Oduk Y, Lou X . Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell-Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine. Circulation. 2017; 137(16):1712-1730. PMC: 5903991. DOI: 10.1161/CIRCULATIONAHA.117.030785. View

16.

Kensah G, Gruh I, Viering J, Schumann H, Dahlmann J, Meyer H . A novel miniaturized multimodal bioreactor for continuous in situ assessment of bioartificial cardiac tissue during stimulation and maturation. Tissue Eng Part C Methods. 2010; 17(4):463-73. PMC: 3103055. DOI: 10.1089/ten.TEC.2010.0405. View

17.

Ueda Y, Slabaugh T, Walker A, Ontiveros E, Sosa P, Reader R . Heart Rate and Heart Rate Variability of Rhesus Macaques () Affected by Left Ventricular Hypertrophy. Front Vet Sci. 2019; 6:1. PMC: 6349711. DOI: 10.3389/fvets.2019.00001. View

18.

Zhang B, Montgomery M, Chamberlain M, Ogawa S, Korolj A, Pahnke A . Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis. Nat Mater. 2016; 15(6):669-78. PMC: 4879054. DOI: 10.1038/nmat4570. View

19.

Shiba Y, Fernandes S, Zhu W, Filice D, Muskheli V, Kim J . Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature. 2012; 489(7415):322-5. PMC: 3443324. DOI: 10.1038/nature11317. View

20.

Lanza R, Russell D, Nagy A . Engineering universal cells that evade immune detection. Nat Rev Immunol. 2019; 19(12):723-733. DOI: 10.1038/s41577-019-0200-1. View